NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症治療單克隆抗體的全球市場預測(2020-2026)

Cancer Monoclonal Antibodies Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 986533
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
癌症治療單克隆抗體的全球市場預測(2020-2026) Cancer Monoclonal Antibodies Market 2020-2026
出版日期: 2020年11月11日內容資訊: 英文
簡介

在預測期內,估計用於癌症治療的單克隆抗體的全球市場將顯著增長。單克隆抗體越來越多的批准是推動市場增長的因素。從靶標開發到技術進步,單克隆抗體藥物已成為醫學領域的公認療法。截至2019年11月,美國FDA已批准了六種單克隆抗體療法: crizanlizumab, romosozumab, brolucizumab, risankizumab, polatuzumab vedotin,caplacizumab-yhdp (Cablivi)。單克隆抗體用於治療多種疾病,包括某些類型的癌症。

研究人員必須首先確定合適的抗原進行攻擊,以開發出單克隆抗體。與其他癌症相比,單克隆抗體已被證明對某些癌症有效。用於治療癌症的單克隆抗體是靶向療法,因為它們具有針對癌細胞的特異性靶標,這些靶標針對檢測,附著和侵襲。其他單克隆抗體也可以用作免疫療法,因為它們可以改善免疫系統的反應,從而增加人體發現和攻擊癌細胞的機會。

在地理上,由於癌症患病率上升和對該地區新型癌症治療的新需求,預計亞太地區癌症單克隆抗體市場在預測期內將具有增長潛力。根據世界衛生組織(WHO)的數據,2018年中國的新型癌症數量接近430萬。在印度,2018年的新癌症數量為120萬。這增加了對用於治療該地區的實體瘤和血液系統惡性腫瘤的單克隆抗體療法的需求。

產品發佈,合作夥伴關係和協作是市場進入者為改善市場定位而採取的潛在策略。例如,2018年6月,輝瑞公司宣佈ZIRABEV(貝伐單抗)獲得美國FDA的批准。這包括局部晚期,復發或轉移性非小細胞肺癌(NSCLC),轉移性結直腸癌,不可切除的轉移性腎細胞癌(RCC),復發性膠質母細胞瘤,阿瓦斯汀(貝伐單抗)生物仿製藥,可用於治療五種癌症:持續,復發或轉移性宮頸癌。繼2019年3月TRAZIMERA以來,這是該公司的第二種經FDA批准的腫瘤學單克隆抗體生物仿製藥。這種新型生物仿製藥有助於增加獲得有影響力的治療方法的機會,並加速市場競爭。結果,這最終可以降低成本並幫助滿足罹患癌症的患者的各種需求。

本報告對全球癌症治療性單克隆抗體市場進行了研究和分析,並提供了有關市場概況,市場決定因素,市場細分,競爭狀況,區域分析,主要公司等的系統信息。

目錄

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規章制度

第3章競爭情況

  • 公司股份分析
  • 關鍵策略分析
  • 主要公司分析
    • Amgen, Inc.
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche AG
    • Merck & Co., Inc.
    • Novartis AG

第4章市場決定因素

  • 成長因素
  • 抑制因素
  • 市場機會

第5章市場細分

  • 按類型劃分的市場
    • 無遮蓋型
    • 組合類型
    • 其他(雙特異性)
  • 按應用市場
    • 乳腺癌
    • 肝癌
    • 血液癌
    • 腦瘤
    • 大腸癌
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他地區

第7章公司簡介

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon, Ltd.
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Company, Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline plc
  • Innate Pharma S.A.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Oncologie, Inc.
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co., Ltd.
目錄
Product Code: OMR2022828

Global Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026

The global cancer monoclonal antibodies market is estimated to witness significant growth during the forecast period. Increasing approvals for monoclonal antibodies is driving the market growth. Monoclonal antibody drugs have become established therapy in the area of medicine ranging from development of targets to improvement in technologies. As of November 2019, the US FDA approved 6 monoclonal antibody therapeutics, which include crizanlizumab, romosozumab, brolucizumab, risankizumab, polatuzumab vedotin, and caplacizumab-yhdp (Cablivi). Monoclonal antibodies are used for the treatment of several diseases, which includes some kinds of cancer.

Researchers need to first identify the right antigen to attack to develop a monoclonal antibody. Monoclonal antibodies have demonstrated to be more beneficial against some cancers compared to others. Some monoclonal antibodies are used for the treatment of cancer are known as targeted therapy as they have a particular target on a cancer cell that intends to discover, attach to, and attack. However, other monoclonal antibodies works as immunotherapy as they supports to make the response of immune system better which in turn, supports the body to discover and attack cancer cells more potentially.

Geographically, Asia-Pacific cancer monoclonal antibodies market is estimated to witness potential growth during the forecast period owing to the increasing prevalence of cancer and emerging demand for novel cancer therapies in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China were nearly 4.3 million in 2018. In India, the number of new cancer incidences were 1.2 million in 2018. This leads to an increasing demand for monoclonal antibodies therapy in the region for the treatment of both solid tumors and hematologic malignancies.

Some key players in the market include Amgen Inc., Eli Lilly & Co., F. Hoffman-La Roche AG, Merck & Co., Inc., and Novartis AG. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in June 2018, Pfizer Inc. declared the US FDA approval of ZIRABEV (bevacizumab-bvzr). It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer. It is the company's second oncology monoclonal antibody biosimilar gained FDA approval, following TRAZIMERA (trastuzumab-qyyp) in March 2019. This new biosimilar can support to increase access to impactful therapies, accelerating market competition. As a result, this may eventually reduce costs and support meet the diverse requirements of patients suffering from cancer.

Research Methodology

The market study of the global cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Cancer Monoclonal Antibodies Market Research and Analysis by Type

2. Global Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers:

Comprehensive research methodology of the global cancer monoclonal antibodies market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global cancer monoclonal antibodies market.

Insights about market determinants which are stimulating the global cancer monoclonal antibodies market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Amgen, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Eli Lilly and Co.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. F. Hoffmann-La Roche AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Merck & Co., Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Novartis AG
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Cancer Monoclonal Antibodies Market by Type
    • 5.1.1. Naked
    • 5.1.2. Conjugated
    • 5.1.3. Others (Bispecific)
  • 5.2. Global Cancer Monoclonal Antibodies Market by Application
    • 5.2.1. Breast Cancer
    • 5.2.2. Liver Cancer
    • 5.2.3. Blood Cancer
    • 5.2.4. Brain Cancer
    • 5.2.5. Colorectal Cancer
    • 5.2.6. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie, Inc.
  • 7.2. Amgen, Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Biocon, Ltd.
  • 7.6. Bristol Myers Squibb Co.
  • 7.7. Daiichi Sankyo Company, Ltd.
  • 7.8. Eli Lilly and Co.
  • 7.9. F. Hoffmann-La Roche AG
  • 7.10. Genmab A/S
  • 7.11. GlaxoSmithKline plc
  • 7.12. Innate Pharma S.A.
  • 7.13. Johnson & Johnson Services, Inc.
  • 7.14. Merck & Co., Inc.
  • 7.15. Mylan N.V.
  • 7.16. Novartis AG
  • 7.17. Oncologie, Inc.
  • 7.18. Pfizer Inc.
  • 7.19. Spectrum Pharmaceuticals, Inc.
  • 7.20. Takeda Pharmaceutical Co., Ltd.

LIST OF TABLES

  • 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL NAKED MONOCLONAL ANTIBODIESMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL CONJUGATED MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL OTHER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL CANCERMONOCLONAL ANTIBODIESMARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 6. GLOBAL MONOCLONAL ANTIBODIESIN BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL MONOCLONAL ANTIBODIES IN LIVER CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MONOCLONAL ANTIBODIES IN BLOODCANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL MONOCLONAL ANTIBODIES IN BRAIN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL MONOCLONAL ANTIBODIES IN COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL MONOCLONAL ANTIBODIES IN OTHER CANCER TYPESMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 16. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 18. EUROPEAN CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 2. GLOBALCANCER MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2019-2026 ($ MILLION)